Innovative Technologies in multimarketing agreements
This article was originally published in Clinica
Executive Summary
Innovative Technologies, a UK developer of polymer-based woundcare products, recorded turnover of £42,572 ($66,412) for the first six months ended June 30th, 1995. The company, which posted losses of £1.2 million for the period against a loss of £0.6 million in the 1994 first half, was floated on the London stock exchange in December 1994. Chairman Ronald Somerville says the company is aiming for annual woundcare sales in excess of £10 million within the next two years.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.